Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCV Chemotherapy in Recurrent IDH-mutant High-grade Glioma
NCT02333513Unknown
- Sponsor
- Hebei Yanda Hospital
- Start
- Feb 2015
- Primary completion
- Dec 2017
- Modality
- DNA Intercalators/Alkylators, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Open-label trial of lomustine, vincristine and procarbazine in glioma, sponsored by Hebei Yanda Hospital. Primary endpoint: Progression-Free Survival at 12 months. Status: unknown.
02
Drugs
lomustinevincristineprocarbazine
03
Conditions
glioma
Beyond the preview
Go deeper on NCT02333513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02333513.